Cytarabine dose for acute myeloid leukemia

New England Journal of Medicine

Volumn 364, Issue 11, 2011, Pages 1027-1036

  Löwenberg, Bob ^a   Pabst, Thomas ^h   Vellenga, Edo ^b   Van Putten, Wim ^a   Schouten, Harry C ^c   Graux, Carlos ^m   Ferrant, Augustin ⁿ   Sonneveld, Pieter ^a   Biemond, Bart J ^d   Gratwohl, Alois ⁱ   De Greef, Georgine E ^a   Verdonck, Leo F ^e   Schaafsma, Martijn R ^f   Gregor, Michael ^j   Theobald, Matthias ^p   Schanz, Urs ^k,l   Maertens, Johan ^o   Ossenkoppele, Gert J ^g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j LUZERNER KANTONSSPITAL   (Switzerland)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l University Hospital   (Switzerland)

^m UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

ⁿ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESPONSE; EVENT FREE SURVIVAL; EYE TOXICITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SURVIVAL RATE; THROMBOCYTE COUNT;

EID: 79952808421     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1010222     Document Type: Article

References (24)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62. [Erratum, N Engl J Med 1999;341:1484.]
2. Herzig RH, Lazarus HM, Wolff SN, Philips GL, Herzig GP. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 1985;3:992-7. (Pubitemid 15028571)
3. Wolff SN, Marion J, Stein RS, et al. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphoblastic leukemia in first remission: a pilot study. Blood 1985;65:1407-11. (Pubitemid 15057947)
4. Phillips GL, Reece DE, Shepherd JD, et al. High dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991;77:1429-35.
5. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903. (Pubitemid 24299870)
6. Farag SS, Ruppert AS, Mrózek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005;23:482-93. (Pubitemid 46224225)
7. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59.
8. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74.
9. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7. (Pubitemid 26068888)
10. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of highdose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-51. (Pubitemid 26357364)
11. Büchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006;24:2480-9. (Pubitemid 46655599)
12. Bradstock KF, Matthews JP, Lowenthal RM, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing highdose cytarabine. Blood 2005;105:481-8. (Pubitemid 40070725)
13. Greenberg P, Cox C, Lebeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. [Erratum, Blood 1998;91:1100.]
14. Löwenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997;15:3496-506. (Pubitemid 27527723)
15. Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-52. (Pubitemid 37010778)
16. Löwenberg B, Ossenkoppele GJ, Van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48. [Erratum, N Engl J Med 2010;362:1155.]
17. van der Holt B, Löwenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005; 106:2646-54. (Pubitemid 41510736)
18. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26:4791-7.
19. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 study. Blood 2010 August 6 (Epub ahead of print).
20. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood 2005;105:3420-7. (Pubitemid 40628181)
21. Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-β-D-arabinofuranosylcytosine 5¢-triphosphate accumulation in leukemia cells during high-dose 1-β-Darabinofuranosylcytosine therapy. Cancer Res 1987;47:3005-11. (Pubitemid 17113452)
22. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failurefree and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17:3767-75.
23. Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16) (p13;q22): results from CALGB 8461. J Clin Oncol 2004;22:1087-94.
24. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-9. (Pubitemid 28440576)